KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Shares Outstanding (2016 - 2025)

Travere Therapeutics' Shares Outstanding history spans 15 years, with the latest figure at $90.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 3.97% year-over-year to $90.9 million; the TTM value through Dec 2025 reached $90.9 million, up 3.97%, while the annual FY2025 figure was $90.9 million, 3.97% up from the prior year.
  • Shares Outstanding reached $90.9 million in Q4 2025 per TVTX's latest filing, up from $89.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $90.9 million in Q4 2025 to a low of $60.4 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $73.8 million, with a median of $75.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: surged 40.05% in 2021, then grew 1.98% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $62.5 million in 2021, then increased by 2.88% to $64.3 million in 2022, then increased by 17.23% to $75.4 million in 2023, then grew by 16.04% to $87.5 million in 2024, then increased by 3.97% to $90.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Shares Outstanding are $90.9 million (Q4 2025), $89.5 million (Q3 2025), and $89.1 million (Q2 2025).